February 01, 2015 6:12 PM ET

Biotechnology

Company Overview of Inotek Pharmaceuticals Corporation

Company Overview

Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma. Its lead product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye’s natural pressure control mechanism. The company is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals Corporation was founded in 1999 and ...

131 Hartwell Avenue

1st Floor

Suite 105

Lexington, MA 02421

United States

Founded in 1999

4 Employees

Phone:

781-676-2100

Fax:

781-676-2155

Key Executives for Inotek Pharmaceuticals Corporation

Chief Executive Officer
Age: 53
Vice President of Finance
Age: 63
Chief Scientific Officer and Executive Vice President
Age: 56
Chief Medical Officer and Executive Vice President
Age: 55
Compensation as of Fiscal Year 2014.

Inotek Pharmaceuticals Corporation Key Developments

Inotek Pharmaceuticals, Inc. Appoints David. P. Southwell as President, Chief Executive Officer and to its Board

Inotek Pharmaceuticals Inc. announced that David. P. Southwell has been named President and Chief Executive Officer. Mr. Southwell will also join the Board of Directors. Mr. Southwell brings to Inotek more than 20 years of experience in biotechnology and pharmaceuticals including financings, mergers and acquisitions, and general corporate leadership. Prior to joining Inotek, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Human Genome Sciences during the approval and launch of Benlysta(R). He currently serves on the boards of PTC Therapeutics and THL Credit Inc. and on the Board of Overseers of the Tuck School of Business at Dartmouth College.

Inotek Pharmaceuticals Announces Study Results Demonstrating Neuroprotective Properties of Trabodenoson

Inotek Pharmaceuticals Corporation announced the results from a preclinical study demonstrating the ability of trabodenoson, an adenosine A1 mimetic in development for glaucoma, to protect against the loss of retinal ganglion cells in an acute high-ocular-pressure animal model of glaucoma. Retinal ganglion cells are the part of the nervous system responsible for relaying the visual image from the eye to the brain, and their death is what causes the irreversible vision loss associated with glaucoma. The results of this study were presented this month at the 2014 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). This preclinical neuroprotection study was designed to compare the protective effects of trabodenoson and brimonidine in a rat model of ischemia-induced retinal ganglion cell (RGC) death. Trabodenoson was delivered as an eye drop at a clinically relevant dose. Results of the study showed that trabodenoson provided 100% protection against the thinning of the ganglion cell layer (p<=0.001 compared to vehicle-treated eyes).

Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension

Inotek Pharmaceuticals Inc. announced the initiation of a Phase 2 clinical study of its lead product, trabodenoson, in combination with the most widely-prescribed glaucoma drug, the prostaglandin analog latanoprost (LAT), in patients with elevated intraocular pressure (IOP) that remains uncontrolled despite ongoing treatment with latanoprost. The Phase 2 study is a randomized, double-masked, active-controlled, multicenter trial comparing trabodenoson plus LAT, to timolol (the active comparator) plus LAT, in 120 patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG). The study will measure the additive or synergistic IOP lowering effect of trabodenoson when combined with LAT, and will also evaluate the safety and tolerability of the combined treatment regimen. The total treatment time will be 3 months, during which the effect of trabodenoson will be evaluated following twice-a-day dosing (BID) and once-daily dosing (QD). Top line data is expected in the fourth quarter of 2014.

Similar Private Companies By Industry

Company Name Region
Signum Biosciences, Inc. United States
Ster-o-Wave LLC United States
Nanotronics, Inc. United States
Nanomedical Diagnostics, Inc. United States
Tissue Engineering, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Inotek Pharmaceuticals Corporation, please visit www.inotekcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.